Although it is reported that SOX2 may start the tumor initiation process via CDK1 in melanoma [92], knocking-out of SOX2 by CRISPR-Cas9 does not affect melanoma progression and metastasis [91]. The gene discussed is CDK1; the disease is melanoma.